Recursion Pharmaceuticals

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Cyclica Inc. is a Toronto-based company that specializes in enhancing the drug discovery process through its integrated cloud-based platform augmented by artificial intelligence. Founded in 2010, Cyclica offers technologies such as Ligand Design, which generates novel molecules and evaluates their properties, and Ligand Express, a platform that screens small-molecule drugs against structurally-characterized proteins to assess poly-pharmacological profiles. The company's innovative software leverages biophysics and AI to identify potential ligand-protein interactions, enabling health institutions to prioritize candidate drugs, clarify adverse effects, and explore drug repurposing opportunities. Cyclica has also established a strategic partnership with AUM Biosciences to further its mission of improving drug discovery practices.

InVivo AI is a Montreal-based company founded in 2017 that specializes in leveraging artificial intelligence to enhance pharmaceutical research and development, with a particular focus on preclinical toxicology. The company has developed advanced AI methods for molecular representation, structure and ligand-based de novo design, and multiparameter optimization, enabling the creation of novel chemistry to address complex biological challenges.

Vium, Inc. is a biotechnology company founded in 2013 and headquartered in San Mateo, California. It specializes in developing digital biomarkers aimed at enhancing preclinical research and animal welfare. The company is fully accredited by AAALAC International and has received significant commendation for its commitment to the principles of humane animal research. Vium's digital platform, known as Digital Vivarium and Vium Cloud, utilizes advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively collect physiological metrics and behaviors. This innovative approach enables researchers and drug developers to gain improved insights into disease progression, thereby facilitating better decision-making regarding which compounds should progress to clinical trials. Its clientele includes a diverse array of biotechnology, pharmaceutical, and academic institutions, as well as novel therapeutic laboratories, all seeking more sensitive and accurate data for replicable studies.